-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Aligos Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2019 to Q3 2024.
- Aligos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$19.3M, a 6.75% decline year-over-year.
- Aligos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$77M, a 5.78% increase year-over-year.
- Aligos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$87.7M, a 8.71% increase from 2022.
- Aligos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$96M, a 25.2% increase from 2021.
- Aligos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$128M, a 18.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)